Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.14365/5568
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kocabaş, Umut | - |
dc.contributor.author | Ergin, Işıl | - |
dc.contributor.author | Yavuz, Veysel | - |
dc.contributor.author | Altın, Cihan | - |
dc.contributor.author | Kaplan, Mehmet | - |
dc.contributor.author | Oztekin, Guelsuem Meral Yilmaz | - |
dc.contributor.author | Dogdus, Mustafa | - |
dc.date.accessioned | 2024-10-25T15:17:53Z | - |
dc.date.available | 2024-10-25T15:17:53Z | - |
dc.date.issued | 2024 | - |
dc.identifier.issn | 2055-5822 | - |
dc.identifier.uri | https://doi.org/10.1002/ehf2.15049 | - |
dc.identifier.uri | https://hdl.handle.net/20.500.14365/5568 | - |
dc.description.abstract | Aims: We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting. Methods: Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023. Results: The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06-3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27-9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16-6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72-13.20; P < 0.001), the use of angiotensin receptor-neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39-7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49-2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18-2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30-2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45-0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37-0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48-0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49-0.91; P = 0.010) were independently associated with the non-use of SGLT2is. Conclusions: The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease. | en_US |
dc.description.sponsorship | We would like to thank Prof. Dr. Seckin Pehlivanolu for his critical review of this study. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley Periodicals, Inc | en_US |
dc.relation.ispartof | Esc heart failure | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | guideline | en_US |
dc.subject | heart failure | en_US |
dc.subject | sodium-glucose cotransporter 2 inhibitors | en_US |
dc.subject | Esc Guidelines | en_US |
dc.subject | Outcomes | en_US |
dc.title | Real-World Data on Empagliflozin and Dapagliflozin Use in Patients With Heart Failure: the Red-Heart Study | en_US |
dc.type | Article | en_US |
dc.type | Article; Early Access | en_US |
dc.identifier.doi | 10.1002/ehf2.15049 | - |
dc.identifier.pmid | 39340234 | - |
dc.identifier.scopus | 2-s2.0-85205077364 | - |
dc.department | İzmir Ekonomi Üniversitesi | en_US |
dc.authorid | Cakan, Fahri/0000-0002-5427-3480 | - |
dc.authorscopusid | 57211015002 | - |
dc.authorscopusid | 25951372300 | - |
dc.authorscopusid | 55457354700 | - |
dc.authorscopusid | 23979295100 | - |
dc.authorscopusid | 56824971000 | - |
dc.authorscopusid | 57207828905 | - |
dc.authorscopusid | 57204894031 | - |
dc.identifier.wos | WOS:001321727100001 | - |
dc.institutionauthor | … | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.identifier.wosquality | Q2 | - |
item.openairetype | Article | - |
item.openairetype | Article; Early Access | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
crisitem.author.dept | 09.02. Internal Sciences | - |
crisitem.author.dept | 09.02. Internal Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
2
checked on Mar 26, 2025
WEB OF SCIENCETM
Citations
2
checked on Mar 26, 2025
Page view(s)
58
checked on Mar 31, 2025
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.